Effects of beprostaglandin combined with vardenafil on serum levels of AGEs and Ang Ⅱ in patients with type 2 diabetes mellitus and erectile dysfunction
Objective To analyze the effects of beprostaglandin combined with vardenafil on serum levels of advanced glyca-tion end products(AGEs)and angiotensin Ⅱ(Ang Ⅱ)in patients with type 2 diabetes mellitus and erectile dysfunction.Methods From January 2020 to December 2022,100 patients with type 2 diabetes mellitus complicated with erectile dysfunc-tion in our hospital were selected as research objects,and were divided into control group and observation group by random number table method,with 50 cases in each group.Both groups were treated with routine hypoglycemic therapy,the control group was treated with vardenafil,and the observation group was treated with beprostaglandin on the basis of the control group.After 4 weeks of treatment,the clinical effects of the two groups were counted,and the erectile stiffness score(EHS),erectile function,serum AGEs and Ang Ⅱ levels were observed before and after treatment.Results The total effective rate of observation group was higher than that of control group(P＜0.05).Before treatment,there were no significant differences in EHS scores,Ⅱ EF-5 scores,serum AGEs and Ang Ⅱ levels between the two groups(P＞0.05).After treatment,EHS scores and ⅡEF-5 scores in the observation group were higher than those in the control group(P＜0.05),and the levels of serum AGEs and AngⅡ were lower than that in the control group(P＜0.05).Conclusion Beprostaglandin combined with vardenafil is an ideal therapeutic effect for patients with type 2 diabetes mellitus complicated with erectile dysfunction,which can effec-tively increase the number of successful sexual intercourse per week,improve erectile dysfunction,and effectively regulate serum AGEs and AngⅡ levels in patients.
NETL
NSTL
万方数据
